Antihypertensive Drugs

Correct Answer

B — Angiotensin converting enzyme inhibitor

Rationale

Lisinopril is an angiotensin converting enzyme inhibitor. Amlodipine is a dihydropyridine calcium channel blocker. Indapamide is a thiazide-like diuretic. Propranolol is a non-selective beta-adrenergic receptor antagonist.

Correct Answer

C — Sodium-glucose cotransporter 2 inhibitors

Rationale

Dapagliflozin and empagliflozin are sodium-glucose cotransporter 2 inhibitors. Finerenone is a non-steroidal mineralocorticoid receptor antagonist. Sacubitril-valsartan is an angiotensin receptor-neprilysin inhibitor. Furosemide is a loop diuretic.

Correct Answer

A — Non-steroidal mineralocorticoid receptor antagonist

Rationale

Finerenone is a non-steroidal mineralocorticoid receptor antagonist. Spironolactone and eplerenone are steroidal mineralocorticoid receptor antagonists. Empagliflozin is a sodium-glucose cotransporter 2 inhibitor. Losartan is an angiotensin receptor blocker.

Correct Answer

D — Loop diuretics

Rationale

Torsemide is a loop diuretic. Hydrochlorothiazide is a thiazide diuretic. Amiloride is a potassium-sparing diuretic. Spironolactone is a mineralocorticoid receptor antagonist.

Correct Answer

B — Angiotensin receptor blocker

Rationale

Telmisartan is an angiotensin receptor blocker. Ramipril is an angiotensin converting enzyme inhibitor. Aliskiren is a direct renin inhibitor. Nifedipine is a calcium channel blocker.

Correct Answer

C — Selective beta-1 adrenergic receptor antagonist

Rationale

Bisoprolol is a selective beta-1 adrenergic receptor antagonist. Propranolol is a nonselective beta-adrenergic receptor antagonist. Doxazosin is an alpha-1 adrenergic receptor antagonist. Clonidine is a centrally acting alpha-2 adrenergic receptor agonist.

Correct Answer

A — Angiotensin II preferentially constricts the efferent arteriole (the vessel exiting the glomerular capillary tuft), raising intraglomerular hydrostatic pressure; renin-angiotensin-aldosterone system inhibition dilates the efferent arteriole, reducing intraglomerular pressure and decreasing proteinuria

Rationale

Angiotensin II constricts both the afferent and efferent arterioles, but with greater potency at the efferent arteriole (the vessel exiting the glomerular capillary tuft). This preferential efferent constriction maintains or raises intraglomerular hydrostatic pressure even when systemic blood pressure is controlled. The sustained elevation in intraglomerular pressure causes mechanical stress on the glomerular filtration barrier, leading to increased permeability (proteinuria) and over time to glomerulosclerosis and progressive nephron loss. When a renin-angiotensin-aldosterone system inhibitor is given, angiotensin II production or action is reduced, and the efferent arteriole dilates. This lowers intraglomerular hydrostatic pressure, which directly reduces proteinuria and slows glomerulosclerosis. This mechanism operates independently of any effect on systemic blood pressure — it is why renin-angiotensin-aldosterone system inhibitors provide renoprotection beyond what equivalent blood pressure reduction with other drug classes achieves. The expected modest rise in serum creatinine after starting these drugs reflects this intended reduction in glomerular filtration pressure and is not a sign of harm.

Correct Answer

D — A rise of up to 30 percent is acceptable and reflects the intended reduction in intraglomerular pressure; a rise of 30 to 50 percent warrants reassessment for volume depletion or interacting drugs; a rise above 50 percent requires holding the drug

Rationale

When a renin-angiotensin-aldosterone system inhibitor lowers intraglomerular pressure by dilating the efferent arteriole (the vessel exiting the glomerular capillary tuft), the glomerular filtration rate falls modestly — producing a predictable and expected rise in serum creatinine. A rise of up to 30 percent from baseline is the accepted threshold for continuation without dose adjustment; this rise represents the pharmacological mechanism that protects the kidney long-term and does not indicate harm. A rise of 30 to 50 percent should prompt reassessment for precipitating factors: volume depletion from concurrent diuretic use or illness, concurrent use of nonsteroidal anti-inflammatory drugs, or contrast exposure — all of which can amplify the hemodynamic effect on glomerular filtration rate. A rise above 50 percent indicates that the reduction in glomerular filtration rate is excessive and the drug should be held while precipitating factors are identified and corrected. Serum creatinine and potassium should be checked 2 to 4 weeks after initiation and after each dose increase.

Correct Answer

B — By blocking proximal sodium reabsorption, they increase sodium delivery to the macula densa, which restores tubuloglomerular feedback and triggers afferent arteriolar constriction, reducing intraglomerular pressure from the supply side

Rationale

In diabetic and other forms of chronic kidney disease, hyperfiltration occurs partly because increased proximal tubular sodium and glucose reabsorption reduces sodium delivery to the macula densa (the specialized cells that sense tubular sodium concentration). Low macula densa sodium signals that the nephron is underfilled, triggering tubuloglomerular feedback that dilates the afferent arteriole (the vessel supplying the glomerular capillary tuft) to increase glomerular filtration — worsening intraglomerular hypertension. Sodium-glucose cotransporter 2 inhibitors block glucose and sodium reabsorption in the proximal tubule, increasing sodium delivery to the macula densa. Restored sodium sensing reactivates tubuloglomerular feedback, which constricts the afferent arteriole and reduces intraglomerular pressure. This mechanism operates on the afferent side of the glomerulus — complementary to but distinct from renin-angiotensin-aldosterone system inhibitors, which work on the efferent side. This complementarity is the mechanistic basis for combining both classes in the triple renoprotective strategy, and it explains why the renal benefit of sodium-glucose cotransporter 2 inhibitors is independent of their glucose-lowering effect.

Correct Answer

C — Filtered proteins activate proximal tubular cells, triggering inflammation and fibrosis in the interstitium; albumin carries nephrotoxic fatty acids; and complement activated within tubular fluid drives interstitial injury — creating a fibrosis cycle independent of continued glomerular pressure

Rationale

Proteinuria causes tubular and interstitial injury through several simultaneous mechanisms. First, filtered proteins are taken up by proximal tubular epithelial cells and activate nuclear factor kappa-B and other inflammatory signaling pathways, causing the tubular cells to release chemokines and cytokines that recruit immune cells and promote fibroblast activation in the surrounding interstitium. Second, albumin that passes the glomerular filter carries bound fatty acids and lipids that are directly toxic to proximal tubular cell mitochondria when taken up in excess. Third, filtered complement proteins can be activated within the tubular lumen, generating complement fragments that directly injure tubular cells and the surrounding interstitium. The result is tubulointerstitial fibrosis — even if intraglomerular pressure is subsequently controlled, the fibrotic process already initiated by proteinuria can continue to destroy nephrons. This is why reducing proteinuria — not just blood pressure — is an explicit co-primary treatment goal in chronic kidney disease management, and why a greater than 30 percent reduction in proteinuria following renin-angiotensin-aldosterone system inhibitor initiation is a favorable prognostic marker.

Correct Answer

A — As glomerular filtration falls, less sodium is filtered overall and more is reabsorbed proximally, leaving insufficient sodium reaching the distal convoluted tubule for thiazides to block — their natriuretic target is functionally absent

Rationale

Thiazide diuretics inhibit the sodium-chloride cotransporter in the distal convoluted tubule, a nephron segment that normally handles only 5 to 10 percent of the total filtered sodium load. As glomerular filtration rate declines in advancing chronic kidney disease, the total amount of sodium filtered per unit time decreases proportionally. Simultaneously, proximal tubular sodium reabsorption — which handles the majority of filtered sodium — is relatively preserved and may even be upregulated as surviving nephrons compensate. The net result is that very little sodium reaches the distal convoluted tubule for the thiazide cotransporter to block. No drug can inhibit a transporter that has no substrate to process. Loop diuretics act at the thick ascending limb of the loop of Henle, which handles approximately 25 percent of filtered sodium and retains activity even at substantially reduced glomerular filtration rates, making them the appropriate diuretic class in Stage 4 chronic kidney disease and below. Chlorthalidone and indapamide retain partial efficacy somewhat longer than hydrochlorothiazide at lower estimated glomerular filtration rates, but below approximately 30 mL per minute, even these agents have markedly reduced natriuretic capacity.

Correct Answer

D — Lisinopril and enalapril are removed during hemodialysis, causing erratic plasma levels and reduced blood pressure control between sessions; telmisartan and candesartan are not substantially removed by dialysis and maintain more consistent drug exposure

Rationale

Hemodialysis removes small, water-soluble molecules with low protein binding. Lisinopril is water-soluble and not strongly protein-bound, making it highly dialyzable — a substantial fraction is removed during each hemodialysis session. Enalaprilat (the active form of enalapril) is similarly dialyzable. The result is that blood pressure control is variably affected by the dialysis schedule: levels drop during and after dialysis, and blood pressure rebounds between sessions. This variability complicates management and reduces the reliability of blood pressure control. Telmisartan and candesartan are highly protein-bound and largely eliminated through biliary or fecal pathways, meaning they are not substantially removed by hemodialysis. They maintain more consistent plasma levels across the dialysis cycle, providing more predictable blood pressure and cardiovascular protection. The same principle explains why drugs that are dialyzable require supplemental dosing after dialysis sessions when consistent levels are needed.

Correct Answer

B — The renin-angiotensin-aldosterone system inhibitor dilates the efferent arteriole, reducing intraglomerular pressure from the exit side; the sodium-glucose cotransporter 2 inhibitor restores tubuloglomerular feedback, constricting the afferent arteriole and reducing pressure from the entry side; finerenone blocks mineralocorticoid receptor-driven inflammation and fibrosis, targeting the tissue injury pathway

Rationale

The three drug classes in the triple renoprotective strategy address three mechanistically distinct pathways of nephron loss in type 2 diabetic chronic kidney disease. Renin-angiotensin-aldosterone system inhibitors reduce angiotensin II production or action, dilating the efferent arteriole (the vessel exiting the glomerular capillary tuft) and lowering intraglomerular hydrostatic pressure from the outflow side. They also reduce angiotensin II-driven stimulation of transforming growth factor beta, a key fibrotic mediator. Sodium-glucose cotransporter 2 inhibitors block proximal sodium reabsorption, increasing sodium delivery to the macula densa, restoring tubuloglomerular feedback, and causing the afferent arteriole (the vessel supplying the glomerulus) to constrict — reducing intraglomerular pressure from the inflow side. This complementary hemodynamic action is why combining both classes reduces proteinuria more than either alone. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, blocks aldosterone-driven inflammatory and fibrotic gene expression in the glomerulus and interstitium — targeting the tissue injury pathway that drives progression even when pressure is controlled. Together, these three mechanisms address the full spectrum of progressive nephron loss in this population.

Correct Answer

C — Volume depletion from the illness reduces renal perfusion; continuing the diuretic worsens volume depletion while continuing the renin-angiotensin-aldosterone system inhibitor dilates the efferent arteriole and removes the compensatory mechanism sustaining glomerular filtration — together they risk precipitating acute kidney injury on chronic kidney disease

Rationale

During acute illness with vomiting, diarrhea, or fever and poor oral intake, intravascular volume falls. When renal perfusion is reduced, the kidney compensates by activating the renin-angiotensin-aldosterone system — angiotensin II constricts the efferent arteriole to maintain intraglomerular pressure and preserve the glomerular filtration rate despite lower arterial pressure. This is a critical adaptive response in the setting of volume depletion. If a renin-angiotensin-aldosterone system inhibitor is continued during this period, it dilates the efferent arteriole and removes this compensatory mechanism, causing the glomerular filtration rate to fall precipitously. Continuing the diuretic simultaneously removes more volume, compounding the insult. In patients with chronic kidney disease, who have reduced nephron reserve and less capacity to tolerate acute falls in glomerular filtration rate, this combination can cause severe acute kidney injury superimposed on chronic kidney disease. Patients on renin-angiotensin-aldosterone system inhibitors and diuretics should be given explicit sick-day guidance to temporarily hold both medications when they develop illnesses associated with significant fluid losses, and to restart once they are drinking normally and volume status is restored.

Correct Answer

D — Continue losartan — a 22 percent rise in creatinine is within the acceptable 30 percent threshold, reflects the intended reduction in intraglomerular pressure that provides long-term renoprotection, and does not indicate harm

Rationale

A rise in serum creatinine of up to 30 percent after starting a renin-angiotensin-aldosterone system inhibitor in chronic kidney disease is expected and acceptable. Losartan reduces angiotensin II-mediated efferent arteriolar constriction, causing the efferent arteriole (the vessel exiting the glomerular capillary tuft) to dilate. This reduces intraglomerular hydrostatic pressure, which is the primary mechanism of renoprotection — it directly reduces proteinuria and slows glomerulosclerosis. The modest fall in glomerular filtration rate that results from lower intraglomerular pressure is reflected as a rise in serum creatinine. This is the pharmacological goal, not an adverse effect. A 22 percent rise falls well within the acceptable threshold. Potassium at 4.6 milliequivalents per liter is within normal range. The patient is asymptomatic and euvolemic. Stopping the drug at this point would deprive her of proven long-term renal protection based on a laboratory finding that reflects the drug working correctly. Creatinine should be rechecked in 2 to 4 weeks to confirm stability.

Correct Answer

A — A loop diuretic such as torsemide — thiazide efficacy is markedly reduced at an estimated glomerular filtration rate of 24 because insufficient sodium reaches the distal convoluted tubule; loop diuretics acting at the thick ascending limb remain effective at this level of renal function

Rationale

At an estimated glomerular filtration rate of 24 mL per minute per 1.73 m², the patient is in Stage 4 chronic kidney disease. Thiazide diuretics act at the distal convoluted tubule, which handles only 5 to 10 percent of filtered sodium under normal conditions and receives even less as glomerular filtration falls. Below an estimated glomerular filtration rate of approximately 30 mL per minute, there is insufficient sodium arriving at the distal convoluted tubule to produce meaningful natriuresis — thiazide diuretics are largely ineffective regardless of dose. Loop diuretics act at the thick ascending limb of the loop of Henle, which handles approximately 25 percent of filtered sodium and remains active and accessible even at this level of renal function. Torsemide is preferred over furosemide in this setting because of its more predictable oral bioavailability. Spironolactone should be used with caution in Stage 4 chronic kidney disease because the already-compromised renal potassium excretion capacity substantially increases hyperkalemia risk, particularly when combined with ramipril.

Correct Answer

C — Dapagliflozin protects the kidney by increasing sodium delivery to the macula densa, restoring tubuloglomerular feedback and reducing intraglomerular pressure through afferent arteriolar constriction — a mechanism complementary to but distinct from losartan's efferent arteriolar dilation

Rationale

Dapagliflozin is added in this patient primarily for renoprotection, not glycemic control. By inhibiting sodium-glucose cotransporter 2 in the proximal tubule, dapagliflozin prevents glucose and sodium from being reabsorbed in that segment, increasing the delivery of both to the macula densa (the specialized distal tubular cells that sense sodium concentration and regulate glomerular blood flow through tubuloglomerular feedback). In diabetic chronic kidney disease, proximal sodium reabsorption is upregulated, reducing macula densa sodium delivery and causing pathological afferent arteriolar dilation that drives hyperfiltration and intraglomerular hypertension. Dapagliflozin corrects this by restoring macula densa sodium sensing, re-engaging tubuloglomerular feedback, and constricting the afferent arteriole (the vessel supplying the glomerular capillary tuft) — reducing intraglomerular pressure from the supply side. Losartan reduces intraglomerular pressure from the exit side by dilating the efferent arteriole. Together they address both hemodynamic mechanisms of intraglomerular hypertension. Clinical trial evidence showed that dapagliflozin reduced the primary renal composite endpoint by 39 percent in chronic kidney disease with and without diabetes, confirming that this renoprotection is independent of glucose lowering.

Correct Answer

B — Finerenone — it is a non-steroidal mineralocorticoid receptor antagonist that achieves antifibrotic and anti-inflammatory mineralocorticoid receptor blockade with a lower risk of hyperkalemia than steroidal agents at the doses used for renoprotection

Rationale

Finerenone is a non-steroidal mineralocorticoid receptor antagonist that differs structurally and pharmacologically from spironolactone and eplerenone. Its non-steroidal scaffold confers distinct receptor binding kinetics that, at the doses proven effective for renoprotection in type 2 diabetic chronic kidney disease, produce less potassium retention than steroidal mineralocorticoid receptor antagonists at equivalent antifibrotic doses. This lower hyperkalemia risk makes finerenone the appropriate choice when spironolactone's potassium effect is limiting therapy. Additionally, finerenone does not bind androgen or progesterone receptors — avoiding the gynecomastia, breast tenderness, and sexual adverse effects associated with spironolactone. Eplerenone is a selective steroidal mineralocorticoid receptor antagonist that avoids sex hormone effects but does not meaningfully reduce hyperkalemia risk compared with spironolactone at equivalent doses — it is therefore not the preferred solution when hyperkalemia is the limiting problem in advanced chronic kidney disease. Amiloride blocks epithelial sodium channels but is not a mineralocorticoid receptor antagonist and does not target the inflammatory and fibrotic pathways that finerenone addresses in this context.